Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: A randomised, placebo-controlled study

Ken Ohta, Masakazu Ichinose, Yuji Tohda, Michael Engel, Petra Moroni-Zentgraf, Satoko Kunimitsu, Wataru Sakamoto, Mitsuru Adachi

Research output: Contribution to journalArticlepeer-review

75 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: A randomised, placebo-controlled study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology

Nursing and Health Professions